ER+/HER2- Breast Cancer Clinical Trial Pipeline Analysis: 75+ Key Companies Shaping the Future of ER+/HER2- Breast Cancer Therapeutics | DelveInsight

DelveInsight's ER+/HER2- Breast Cancer Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline ER+/HER2- Breast Cancer therapies in various stages of clinical development. The report provides insights into 75+ companies and 80+ pipeline drugs in the ER+/HER2- Breast Cancer pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the ER+/HER2- Breast Cancer Clinical Trial Landscape Report

• DelveInsight's ER+/HER2- Breast Cancer pipeline report depicts a robust space with 75+ companies working to develop 80+ pipeline therapies for ER+/HER2- Breast Cancer treatment.
• Key ER+/HER2- Breast Cancer companies such as AstraZeneca, Bristol-Myers Squibb, Marengo Therapeutics, Avenzo Therapeutics, Inc., BeOne Medicines, Hoffmann-La Roche, Sanofi, Merck Sharp & Dohme Corp, and others.
• Promising ER+/HER2- Breast Cancer pipeline therapies in various stages of development include AZD9833, Iza-bren, STAR0602, AVZO-023, BGB-21447, and others.

Request a sample and discover the recent advances in ER+/HER2- Breast Cancer treatment drugs https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is ER+/HER2- Breast Cancer?

ER+/HER2- Breast Cancer is the most common subtype of breast cancer, characterized by tumors that express estrogen receptors (ER-positive) but lack overexpression of the human epidermal growth factor receptor 2 (HER2-negative) protein. In this subtype, estrogen stimulates tumor growth, making hormone-based therapies particularly effective. ER+/HER2- cancers generally grow more slowly than other breast cancer types and often have a relatively favorable prognosis, especially when diagnosed early.
Signs and symptoms may include a lump or thickening in the breast or underarm, changes in breast size or shape, skin dimpling, discharge, redness or scaling of the breast skin, and persistent breast pain. Diagnosis typically involves imaging and laboratory tests, followed by biopsy to confirm the presence of cancer and determine receptor status. Treatment may include surgery, radiation therapy, endocrine therapies, targeted therapies, and chemotherapy depending on disease stage and patient characteristics.

Emerging ER+/HER2- Breast Cancer Drug Profiles

AZD9833: AstraZeneca
AZD9833 (camizestrant) is a next-generation oral selective estrogen receptor degrader (SERD) and pure estrogen receptor antagonist designed to fully degrade ERα and overcome resistance associated with ESR1 mutations. In early-phase studies, camizestrant showed favorable tolerability and clinical activity across ESR1-mutant and wild-type HR+/HER2- advanced breast cancer. Currently, the drug is in Phase III development for the treatment of 1st-line HR+ HER2- ESR1m breast cancer.

Iza-bren: Bristol-Myers Squibb
Iza-bren (izalontamab brengitecan; BL-B01D1) is a first-in-class bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3. It is designed for advanced solid tumors, including ER+/HER2- breast cancer, and is linked to a topoisomerase I inhibitor payload. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with ER+/HER2- breast cancer.

STAR0602: Marengo Therapeutics
STAR0602 (invikafusp alfa), developed by Marengo Therapeutics, is a first-in-class, clinical-stage bi-functional fusion protein immunotherapy that targets specific variable (Vβ) regions of the T cell receptor (TCR). The drug is designed to selectively activate and expand effector memory Vβ T cells capable of generating durable, tumor-directed immune responses. According to the company's pipeline, the drug is in Phase II development for HR+, HER2-, Advanced Breast Cancer.

Learn more about the novel and emerging ER+/HER2- Breast Cancer pipeline therapies https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the ER+/HER2- Breast Cancer Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key ER+/HER2- Breast Cancer Companies: AstraZeneca, Bristol-Myers Squibb, Marengo Therapeutics, Avenzo Therapeutics, Inc., BeOne Medicines, Hoffmann-La Roche, Ellipses Pharma, TYK Medicine, Recursion Pharmaceuticals, Kind Pharmaceuticals LLC, Sanofi, Merck Sharp & Dohme Corp
• Key ER+/HER2- Breast Cancer Pipeline Therapies: AZD9833, Iza-bren, STAR0602, AVZO-023, BGB-21447, Giredestrant, Vosilasarm (EP0062), TYK-00540, GTAEXS617, AND019, BLU956, Belzutifan

Dive deep into rich insights for new drugs for ER+/HER2- Breast Cancer treatment, visit https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. ER+/HER2- Breast Cancer Pipeline Report Introduction
2. ER+/HER2- Breast Cancer Pipeline Report Executive Summary
3. ER+/HER2- Breast Cancer: Overview
4. ER+/HER2- Breast Cancer Pipeline Therapeutics
5. ER+/HER2- Breast Cancer Therapeutic Assessment
6. ER+/HER2- Breast Cancer - DelveInsight's Analytical Perspective
7. ER+/HER2- Breast Cancer Pipeline: Late Stage Products (Phase III)
8. ER+/HER2- Breast Cancer Pipeline: Mid Stage Products (Phase II)
9. ER+/HER2- Breast Cancer Pipeline: Early Stage Products (Phase I)
10. ER+/HER2- Breast Cancer Pipeline: Preclinical and Discovery Stage Products
11. ER+/HER2- Breast Cancer Pipeline: Unknown Stage Products
12. Inactive Products in the ER+/HER2- Breast Cancer Pipeline
13. ER+/HER2- Breast Cancer Key Companies
14. ER+/HER2- Breast Cancer Key Products
15. ER+/HER2- Breast Cancer Unmet Needs
16. ER+/HER2- Breast Cancer Market Drivers and Barriers
17. ER+/HER2- Breast Cancer Future Perspectives and Conclusion
18. ER+/HER2- Breast Cancer Analyst Views
19. Appendix

For further information on the ER+/HER2- Breast Cancer pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.